OpenAlex
PricingAboutJobs
Log inGet started
Work

Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

HTML

Year: 2020
Type: article
Source: Bioorganic & Medicinal Chemistry Letters
DOI: 10.1016/j.bmcl.2020.127433
Authors: Neil P. Grimster, Lakshmaiah Gingipalli, Bernard Barlaam, Qibin Su, XiaoLan Zheng, David Watson, Haixia Wang, Iain Simpson, Andy Pike, Amber Balazs, Scott Boiko, Timothy P. Ikeda, Anna C. Impastato, Natalie H. Jones, Sameer Kawatkar, Paul Kemmitt, Scott Lamont, Joe Patel, Jon Read, Ujjal Sarkar, Li Sha, Ronald C. Tomlinson, Haiyun Wang, David M. Wilson, Troy E. Zehnder, Lianghe Wang, Peng Wang, Frederick W. Goldberg, Wenlin Shao, Stephen Fawell, Hannah Dry, James E. Dowling, Scott D. Edmondson
Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom), Pharmaron (China)
Language: English

Topic: Heterocyclic Compound Synthesis and Bioactivity
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4229597174
FWCI: 0.474
Cites: 24
Cited by: 13
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms